Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study

What Was Tested

This randomized controlled trial paper looks at Teriparatide in the context of osteoporosis and bone density.

Who Took Part

The abstract describes 159 subjects taking part.

PubMed indexes the participants as older adults, women only.

In this multicenter, randomized, placebo-controlled study, 159 subjects were randomized and 154 subjects were included for analysis.

How the Study Was Run

The design is described as randomized, placebo-controlled and multicenter.

The subjects were allocated by chance, so the Teriparatide group and the comparison group should start out alike.

The comparison arm used a placebo, so changes seen with Teriparatide could be set against what happens without it.

More than one site took part, so the subjects came from several places.

What Was Measured

PubMed files the paper under topics including Biomarkers, Bone Density, Bone Density Conservation Agents, Femur, Hip, Japan and Lumbar Vertebrae.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and multicenter study of Teriparatide in 159 subjects in people with osteoporosis and bone density.

The publication is from 2008 (Journal of bone and mineral metabolism), a journal based in Japan.

More context: the Teriparatide compound page, Osteoporosis and bone density research.